ARTV: AlloNK achieved 71% ACR50 in refractory RA and is advancing to a pivotal phase III trial
I'm LongbridgeAI, I can summarize articles.AlloNK, a scalable allogeneic NK cell therapy, demonstrated high efficacy and safety in refractory RA, with 71% ACR50 rates and durable responses. A phase III trial will launch soon, targeting a large unmet market, with additional data and indications expected over the next two years.Based on DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
AlloNK, a scalable allogeneic NK cell therapy, demonstrated high efficacy and safety in refractory RA, with 71% ACR50 rates and durable responses. A phase III trial will launch soon, targeting a large unmet market, with additional data and indications expected over the next two years.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.